International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV.

Autor: Singer S; Division of Epidemiology and Health Services Research, Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), University Medical Centre of Johannes Gutenberg University, Mainz, Germany., Amdal CD; Department of Oncology, Oslo University Hospital, Oslo, Norway., Hammerlid E; Department of Otolaryngology and Head and Neck Surgery, Sahlgrenska University Hospital, Gothenburg University, Gothenburg, Sweden., Tomaszewska IM; Department of Medical Didactics, Jagiellonian University Medical College, Krakow, Poland., Castro Silva J; Department of Otolaryngology, Head and Neck Surgery, Instituto Português de Oncologia Francisco Gentil do Porto, Porto, Portugal., Mehanna H; Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, United Kingdom., Santos M; Radiation Oncology Department, Brasilia University Hospital, Brasilia, Brazil., Inhestern J; Clinic of Otorhinolaryngology, Jena University Hospital, Jena, Germany., Brannan C; Lynda Jackson Macmillan Centre, East & North Hertfordshire NHS Trust incorporating Mount Vernon Cancer Centre, Northwood, United Kingdom., Yarom N; Oral Medicine Unit, Sheba Medical Center, Tel-Hashomer, Israel and School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel., Fullerton A; Department of Speech, Language and Hearing Sciences, College of Public Health and Health Professions, University of Florida, Gainesville, Florida., Pinto M; Supportive Care Department, Istituto Nazionale Tumori -IRCCS- Fondazione G. Pascale, Naples, Italy., Arraras JI; Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain., Kiyota N; Department of Medical Oncology and Hematology, Kobe University Hospital Cancer Center, Kobe, Japan., Bonomo P; Radiation Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy., Sherman AC; Behavioral Medicine Division, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas., Baumann I; Department of Otolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany., Galalae R; Department of Radiation Oncology, EVK Gelsenkirchen, University Duisburg-Essen, Gelsenkirchen, Germany., Fernandez Gonzalez L; Research and Teaching Unit, Instituto Oncológico Fundación Arturo López Pérez, Santiago, Chile., Nicolatou-Galitis O; Clinic of Hospital Dentistry, Dental Oncology Unit, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece., Abdel-Hafeez Z; Department of Clinical Oncology, Ain Shams-University, Cairo, Egypt., Raber-Durlacher J; Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center (location AMC) and Department of Oral Medicine ACTA, University of Amsterdam and VU University, Amsterdam, The Netherlands., Schmalz C; Department of Radiation Therapy, University Hospital Schleswig-Holstein, Kiel, Germany., Zotti P; Department of Psychology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy., Boehm A; Department of Otolaryngology Head and Neck Surgery, St. Georg Hospital, Leipzig, Germany., Hofmeister D; Department of Medical Psychology, University Hospital Leipzig, Leipzig, Germany., Krejovic Trivic S; Clinic of Otorhinolaryngology and Maxillofacial Surgery, Faculty of Medicine, University of Belgrade, Belgrade, Serbia., Loo S; Department of Oncology, Colchester Hospital University NHS Foundation Trust, Colchester, United Kingdom., Chie WC; Department of Family Medicine, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan., Bjordal K; Department of Research Support Services, Oslo University Hospital, and University of Oslo, Oslo, Norway., Brokstad Herlofson B; Department of Oral Surgery and Oral Medicine, University of Oslo, and Department of Otorhinolaryngology - Head and Neck Surgery Division for Head, Neck and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway., Grégoire V; Radiation Oncology Dept & Center for Molecular Imaging and Experimental Radiotherapy, Université Catholique de Louvain and St-Luc University Hospital, Brussels, Belgium., Licitra L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, and University of Milan, Milan, Italy.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2019 Jun; Vol. 41 (6), pp. 1725-1737. Date of Electronic Publication: 2019 Jan 12.
DOI: 10.1002/hed.25609
Abstrakt: Background: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43).
Methods: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons.
Results: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales.
Conclusions: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
(© 2019 Wiley Periodicals, Inc.)
Databáze: MEDLINE
Externí odkaz: